Hepatitis B: The Pathway to Recovery Through Treatment

Gastroenterology Clinics of North America

Volumn 35, Issue 4, 2006, Pages 895-931

  Hollinger, F Blaine ^a   Lau, Daryl T Y ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; LAMIVUDINE; PEGINTERFERON; TENOFOVIR; VALTORCITABINE;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; FOLLOW UP; GENE AMPLIFICATION; GENOMICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NEPHROTOXICITY; NONHUMAN; REVIEW; SEROLOGY; UNITED STATES; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; UNITED STATES;

EID: 33751357225     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2006.10.002     Document Type: Review

References (121)

1. Centers for Disease Control and Prevention. Hepatitis surveillance report No. 60 (2005), US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta (GA)
2. Ganem D., and Schneider R.J. Hepadnaviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., et al. (Eds). Field Virology. 4th edition (2001), Lippincott Williams & Wilkins, Philadelphia 2923-2969
3. Hadziyannis S.J., and Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34 (2001) 617-624
4. Desmet V.J., Gerber M., Hoofnagle J.H., et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994) 1513-1520
5. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
6. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 105 (1993) 274-278
7. Brunetto M.R., Giarin M.M., Oliveri F., et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 88 (1991) 4186-4190
8. Saldanha J., Gerlich W., Lelie N., et al. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 80 (2001) 63-71
9. Hollinger F.B., and Liang J.T. Hepatitis B virus. In: Knipe D.M., Howley P.M., et al. (Eds). Fields Virology. 4th edition (2001), Lippincott Williams & Wilkins, Philadelphia 2971-3036
10. Busch M.P., Kleinman S.H., Jackson B., et al. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 40 (2000) 143-159
11. Biswas R., Tabor E., Hsia C.C., et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 43 (2003) 788-798
12. Sjogren M.H., and Lemon S.M. Low-molecular-weight IgM antibody to hepatitis B core antigen in chronic infections with hepatitis B virus. J Infect Dis 148 (1983) 445-451
13. Tsuda F., Naito S., Takai E., et al. Low molecular weight (7s) immunoglobulin M antibody against hepatitis B core antigen in the serum for differentiating acute from persistent hepatitis B virus infection. Gastroenterology 87 (1984) 159-164
14. Shiels M.T., Taswell H.F., Czaja A.J., et al. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B. Gastroenterology 93 (1987) 675-680
15. Hayashi J., Noguchi A., Nakashima K., et al. Frequency of concurrence of hepatitis B surface antigen and antibody in a large number of carriers in Okinawa, Japan. Gastroenterol Jpn 25 (1990) 593-597
16. Wang Y.M., Ng W.C., and Lo S.K. Detection of pre-S/S gene mutants in chronic hepatitis B carriers with concurrent hepatitis B surface antibody and hepatitis B surface antigen. J Gastroenterol 34 (1999) 600-606
17. McMahon B.J., Alward W.L., Hall D.B., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 151 (1985) 599-603
18. Beasley R.P., Trepo C., Stevens C.E., et al. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105 (1977) 94-98
19. Papaevangelou G., Tassopoulos N., Roumeliotou-Karayannis A., et al. Etiology of fulminant viral hepatitis in Greece. Hepatology 4 (1984) 369-372
20. Mast E.E., Mahoney F.J., Alter M.J., et al. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine 16 (1998) S48-S51
21. de Franchis R., Meucci G., Vecchi M., et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 118 (1993) 191-194
22. Redeker A.G. Chronic viral hepatitis. In: Vyas G.N., Perkins H.A., and Schmid R. (Eds). Hepatitis and blood transfusion (1972), Grune & Stratton, New York 55-60
23. Seeff L.B., Zimmerman H.J., Wright E.C., et al. Hepatic disease in asymptomatic parenteral narcotic drug abusers: a Veterans Administration collaborative study. Am J Med Sci 270 (1975) 41-47
24. Cooksley W.G., Bradbear R.A., Robinson W., et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 6 (1986) 345-348
25. Liaw Y.F., Tai D.I., Chu C.M., et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
26. Schalm S.W., Thomas H.C., and Hadziyannis S.J. Chronic hepatitis B. In: Popper H., and Schaffner F. (Eds). Progress in liver disease (1990), WB Saunders, New York 443-462
27. Margolis H.S., Alter M.J., and Hadler S.C. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 11 (1991) 84-92
28. Chu C.J., Keeffe E.B., Han S.H., et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 38 (2003) 619-628
29. Brunetto M.R., Oliveri F., Coco B., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36 (2002) 263-270
30. Fattovich G., Pantalena M., Zagni I., et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97 (2002) 2886-2895
31. de Jongh F.E., Janssen H.L., de Man R.A., et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103 (1992) 1630-1635
32. Realdi G., Fattovich G., Hadziyannis S., et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 21 (1994) 656-666
33. Liaw Y.F., Lin D.Y., Chen T.J., et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 9 (1989) 235-241
34. Hui A.Y., Chan H.L., Leung N.W., et al. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol 34 (2002) 569-572
35. Sheu J.C., Sung J.L., Chen D.S., et al. Early detection of hepatocellular carcinoma by real-time ultrasonography: a prospective study. Cancer 56 (1985) 660-666
36. Sheu J.C., Sung J.L., Chen D.S., et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 89 (1985) 259-266
37. Ihde D.C., Sherlock P., Winawer S.J., et al. Clinical manifestations of hepatoma: a review of 6 years' experience at a cancer hospital. Am J Med 56 (1974) 83-91
38. Di Bisceglie A.M., Rustgi V.K., Hoofnagle J.H., et al. NIH conference: hepatocellular carcinoma. Ann Intern Med 108 (1988) 390-401
39. Sjogren M.H., Lemon S.M., Chung W.K., et al. IgM antibody to hepatitis B core antigen in Korean patients with hepatocellular carcinoma. Hepatology 4 (1984) 615-618
40. Kew M.C., and Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 4 (1984) 136-146
41. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 56 (1985) 918-928
42. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 23 (2003) 47-58
43. Crockett S.D., and Keeffe E.B. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 4 (2005) 13
44. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
45. Lai CL. State-of-the-Art Lecture, 2005. Available at: http://209.63.37.57/home/.
46. Yang H.I., Lu S.N., Liaw Y.F., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
47. Perrillo R.P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120 (2001) 1009-1022
48. Janssen H.L., Gerken G., Carreno V., et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30 (1999) 238-243
49. Wong D.K., Cheung A.M., O'Rourke K., et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 119 (1993) 312-323
50. Lau D.T., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997) 1660-1667
51. Fattovich G., Giustina G., Realdi G., et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 26 (1997) 1338-1342
52. Niederau C., Heintges T., Lange S., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
53. Lin S.M., Sheen I.S., Chien R.N., et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (1999) 971-975
54. Yuen M.F., Hui C.K., Cheng C.C., et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34 (2001) 139-145
55. Lok A.S., Chung H.T., Liu V.W., et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105 (1993) 1833-1838
56. Brook M.G., Karayiannis P., and Thomas H.C. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10 (1989) 761-763
57. Lau D., Kleiner D.K., Park Y., et al. Flare of hepatitis B during alpha interferon therapy. [abstract]. Gastroenterology 110 (1996) A1246
58. Nair S., and Perrillo R.P. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?. Hepatology 34 (2001) 1021-1026
59. Hadziyannis S.J., Papatheodoridis G.V., and Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 23 (2003) 81-88
60. Manesis E.K., and Hadziyannis S.J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121 (2001) 101-109
61. Cooksley W.G., Piratvisuth T., Lee S.D., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol 10 (2003) 298-305
62. Lagget M., and Rizzetto M. Current pharmacotherapy for the treatment of chronic hepatitis B. Expert Opin Pharmacother 4 (2003) 1821-1827
63. Dienstag J.L., Perrillo R.P., Schiff E.R., et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333 (1995) 1657-1661
64. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
65. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
66. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 (2000) 172-180
67. Leung N.W., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
68. Chang T.T., Lai C.L., Liaw Y.F., et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years. [abstract]. Antivir Ther 5 Suppl 1 (2000) 44
69. Perrillo R.P., Lai C.L., Liaw Y.F., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002) 186-194
70. Chien R.N., Liaw Y.F., and Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 30 (1999) 770-774
71. Schiff E., Cianciara J., Karayalcin S., et al. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (CHB). J Hepatol 32 Suppl 2 (2000) 99
72. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
73. Dienstag J.L., Cianciara J., Karayalcin S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37 (2003) 748-755
74. Song B.C., Suh D.J., Lee H.C., et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 (2000) 803-806
75. van Nunen A.B., Hansen B.E., Suh D.J., et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52 (2003) 420-424
76. Lee C.M., Ong G.Y., Lu S.N., et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 37 (2002) 669-674
77. Tassopoulos N.C., Volpes R., Pastore G., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29 (1999) 889-896
78. Santantonio T., Mazzola M., Iacovazzi T., et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 32 (2000) 300-306
79. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 (2000) 847-851
80. Papatheodoridis G.V., Dimou E., Laras A., et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36 (2002) 219-226
81. Ono-Nita S.K., Kato N., Shiratori Y., et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29 (1999) 939-945
82. Wai C.T., and Lok A.S. Treatment of hepatitis B. J Gastroenterol 37 (2002) 771-778
83. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 34 (2001) 1225-1241
84. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
85. Lau D.T., Khokhar M.F., Doo E., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32 (2000) 828-834
86. Lewin S.R., Ribeiro R.M., Walters T., et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34 (2001) 1012-1020
87. Liaw Y.F., Chien R.N., Yeh C.T., et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 (1999) 567-572
88. Honkoop P., de Man R.A., Niesters H.G., et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 32 (2000) 635-639
89. Guan R., Lai C.L., and Liaw Y.F. Efficacy and safety of 5 years lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 16 (2001) 60
90. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
91. Yuen M.F., Sablon E., Hui C.K., et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34 (2001) 785-791
92. Chen R.Y., Edwards R., Shaw T., et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37 (2003) 27-35
93. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 16 (2003) 569-596
94. Benhamou Y: Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 44S1 (2006) S90-S94
95. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
96. Marcellin P., Chang T.T., Lim S., et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg + chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time. [abstract]. Hepatology 40 Suppl 1 (2004) 655A
97. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
98. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
99. Westland C., Delaney W., Yang H., et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 125 (2003) 107-116
100. Qi X., Zhu Y., Curtis M., et al. In vitro cross-resistance analysis of the HBV polymerase mutation A181V. [abstract]. J Hepatol 42 Suppl 2 (2005) 194
101. Westland C.E., Yang H., Delaney W.E., et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38 (2003) 96-103
102. Gibbs C.S., Xiong S., Yang H., et al. Resistance surveillance in HBeAg-negative chronic hepatitis B patients treated with adefovir dipivoxil for two years. [abstract]. Antiviral Research 57 (2003) A43
103. Hadziyannis S., Tassopoulos N., Chang T.T., et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology 42 (2005) 754A
104. Hadziyannis S.J., Tassopoulos N., Chang T.T., et al. Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg- chronic hepatitis B (CHB) patients. [abstract]. Gastroenterology 128 Suppl 2 (2005) A693
105. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
106. Lai C.L., Rosmawati M., Lao J., et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123 (2002) 1831-1838
107. Chang T.T., Gish R., de Man R., et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naive patients. Hepatology 40 Suppl 1 (2004) 193A
108. Gish R.G., Chang T.T., de Man R.A., et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (Study ETV-022). [abstract 181]. Hepatology 42 Suppl 1 (2005) 267A
109. Shouval D., Lai C.L., Cheinquer H., et al. Entecavir demonstrates superior; histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: results of phase III trial ETV-027. [abstract LB 07]. Hepatology 40 Suppl 1 (2004) 728A
110. Tenney D.J., Levine S.M., Rose R.E., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
111. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV-026. [abstract 1152]. Hepatology 40 Suppl 1 (2004) 664A
112. Colonno R., Rose R., Levine S., et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. [abstract 962]. Hepatology 42 Suppl 1 (2005) 573A
113. Tsiang M., Rooney J.F., Toole J.J., et al. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29 (1999) 1863-1869
114. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
115. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
116. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
117. Lau G.K., Tsiang M., Hou J., et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 32 (2000) 394-399
118. Sung J.J.Y., Lai J.Y., Zeuzem S., et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis. J Hepatol 38 (2003) A4313
119. Lok A.S., and McMahon B.J. Chronic hepatitis B: update of recommendations. Hepatology 39 (2004) 857-861
120. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2 (2004) 87-106
121. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B virus and cirrhosis. Hepatology 21 (1995) 77-82